Method Profile
Medium-matched imaging and growth-rate analysis compare drug responses after patient-derived tumor organoids stabilize in two culture conditions.
Identify medium-dependent pharmacology and assess whether response shifts reverse after medium transfer.
Patient-derived pancreatic and colorectal tumor organoids: three paired models in the drug screen and two models in transfer experiments.
Paired Wnt/R-spondin/noggin and OncoPro cultures, stabilized for at least two passages before a 33-compound, four-point screen with imaging over five days.
Patient-derived organoids and paired media
Tumor identity and expansion quality are checked separately; each condition stabilizes before screening.
Imaging and normalized analysis
Medium-matched vehicle and positive controls; normalized organoid growth rate and normalized area over the curve.
Compare media within each patient model. Report completed screens and expansion failures separately, and interpret medium effects for each compound and model.
Paired screening in two media followed by transfer experiments in two models.
Three patient models and 33 compounds; two technical and two biological replicates per patient. Biological replicates were wells cultured separately for at least two passages.
Each model in Wnt and OP, with controls matched to its medium.
Some targeted agents were more active in Wnt; platinum curves were largely flat over the tested range; selected sensitivity shifts were reversible.
A paired comparison found medium-dependent responses to 33 compounds in three pancreatic and colorectal tumor organoid models. Switching medium partly reversed sensitivity, but the study did not test prediction of patient outcomes.
